Evaluation of Cranial Flap Fixation With Montage Flowable Settable Bone Paste
Launched by ABYRX, INC. · Jul 29, 2025
Trial Information
Current as of August 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special bone paste called Montage Flowable, which is designed to help repair and secure pieces of the skull after brain surgery. This paste is mixed right before use and then applied to areas where the skull bone has been cut or needs fixing. Once it hardens, it sticks to the bone and eventually gets absorbed by the body as the bone heals. The goal is to see how well this paste works in helping the skull heal after surgery, especially in smaller areas no larger than about 25 square centimeters.
People who might be eligible for this study are adults over 18 who are having brain surgery in the upper part of the skull where the bone flap (a section of skull bone temporarily removed during surgery) is replaced afterward. To join, most of the edges of the bone flap need to be narrow (less than 3 millimeters wide). The study does not include those who have had previous open brain surgery in the same spot, need a different surgical approach that goes near air spaces in the head, or have certain medical conditions like significant fluid buildup in the brain or recent chemotherapy. If you participate, the Montage Flowable paste will be used during your surgery to help secure your skull bone flap. The trial is not yet recruiting, but if you qualify, this could be a new way to support healing after brain surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female \> 18 years of age
- • 2. Undergoing a cranial procedure in supratentorial location
- • 3. Width of craniotomy kerf line \<3mm for than 75% of the bone flap border
- Exclusion Criteria:
- • 1. Subject requires a procedure involving a translabyrinthine, transsphenoidal, transoral approach, or any procedure that penetrates the air sinus or mastoid air cells.
- • 2. Subject has clinically significant hydrocephalus or clinical evidence of altered CSF dynamics.
- • 3. Subject has undergone a previous, open intracranial neurosurgical procedure in the same anatomical location. (Note: stereotactic biopsy was not exclusionary).
- • 4. Subject requires a craniectomy (the bone flap is not replaced during the current surgery).
- • 5. Subject had radiation treatment to the surgical site, or standard fractionated radiation therapy was planned post index-procedure. (Note: stereotactic radiosurgery prior to the planned index procedure was not an exclusion criterion.)
- • 6. Subject requires a craniotomy across the sinus for which Montage Flowable is applied adjacent to or within the sinus to fixate the cranial flap.
- • 7. Subject has a condition with anticipated survival shorter than six months.
- • 8. Subject has undergone chemotherapy treatment, excluding hormonal therapy, within three weeks prior to the planned index procedure, or use of intracavitary chemotherapy wafer (BCNU) was planned, or chemotherapy treatment was planned within two weeks after the index procedure was performed.
- • 9. Standard use of peri-operative steroids (i.e., corticosteroids) is permitted. Chronic steroid use (defined as daily use of corticosteroids for ≥ 8 weeks) for the purposes of reducing the side effects of chemotherapy and/or radiation therapy for cancer is not exclusionary unless the patient is deemed by the investigator to be suffering from steroid toxicity (i.e., Cushing's syndrome) manifested by symptoms and signs such as thin skin, striae, easy bruising, muscle atrophy, upper body obesity, severe fatigue, etc. Use of corticosteroids on a chronic basis (as defined previously) for purposes other than decreasing the symptoms of systemic chemotherapy is exclusionary unless those steroids were discontinued 4 weeks prior to the planned index procedure.
- • 10. Subject receives warfarin, heparin, other anticoagulant agents on a daily basis and pre-surgical, standard of care drug wash-out did not occur.
- • 11. Subject is pregnant, breast-feeding, or intended to become pregnant during the course of the study.
About Abyrx, Inc.
Abyrx, Inc. is a biopharmaceutical company focused on advancing innovative therapeutic solutions to address unmet medical needs. With a commitment to scientific excellence and patient-centric research, Abyrx specializes in the development of cutting-edge treatments across various therapeutic areas. The company leverages its expertise in drug formulation and delivery technologies to enhance the efficacy and safety profiles of its products. Through rigorous clinical trials and collaborations with healthcare professionals, Abyrx aims to bring transformative therapies to market that improve patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported